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Purpose: This study was conducted to evaluate prognostic factors and cancer-specific 
survival (CSS) in a cohort of 41 patients with urachal carcinoma by use of a Bayesian 
model-averaging approach. 
Materials and Methods: Our cohort included 41 patients with urachal carcinoma who 
underwent extended partial cystectomy, total cystectomy, transurethral resection, 
chemotherapy, or radiotherapy at a single institute. All patients were classified by both 
the Sheldon and the Mayo staging systems according to histopathologic reports and 
preoperative radiologic findings. Kaplan-Meier survival curves and Cox propor-
tional-hazards regression models were carried out to investigate prognostic factors, and 
a Bayesian model-averaging approach was performed to confirm the significance of 
each variable by using posterior probabilities.
Results: The mean age of the patients was 49.88±13.80 years and the male-to-female 
ratio was 24:17. The median follow-up was 5.42 years (interquartile range, 2.8–8.4 
years). Five- and 10-year CSS rates were 55.9% and 43.4%, respectively. Lower Sheldon 
(p=0.004) and Mayo (p＜0.001) stage, mucinous adenocarcinoma (p=0.005), and larger 
tumor size (p=0.023) were significant predictors of high survival probability on the basis 
of a log-rank test. By use of the Bayesian model-averaging approach, higher Mayo stage 
and larger tumor size were significant predictors of cancer-specific mortality in urachal 
carcinoma.
Conclusions: The Mayo staging system might be more effective than the Sheldon stag-
ing system. In addition, the multivariate analyses suggested that tumor size may be 
a prognostic factor for urachal carcinoma.
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The urachus is a vestigial tubular structure that connects 
the urinary bladder to the allantois during early embryonic 
development [1]. Carcinomas of the urachus are believed 
to originate either from malignant transformation of col-
umnar metaplasia from the lining of transitional epi-
thelium or from enteric remnants during embryologic de-
velopment [2]. The estimated annual incidence of urachal 
carcinoma is 0.01% of all cancers in adults; the overall in-
cidence of the disease ranges from 0.55% to 1.20% of blad-
der tumors in Japan and from 0.07% to 0.70% of bladder 
tumors in Western countries [3]. Two systems have been 
proposed for staging urachal cancers. The first system was 
proposed by Sheldon et al. [4] in 1984. A more simplified 
system was recently proposed by the Mayo Clinic, although 
neither system has been validated [5]. However, the two 
staging systems have no criteria on tumor size in urachal 
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cancer. Primary treatment of potentially localized disease 
includes wide local excision of the urachus, umbilicus, and 
surrounding soft tissue combined with partial or radical 
cystectomy and bilateral pelvic lymphadenectomy [6]. 
Debate exists regarding radical versus partial cystectomy 
[7]. The long-term prognosis of urachal cancer is poor be-
cause of its late presentation with local invasion and dis-
tant metastasis despite appropriate surgical treatment 
[8]. 
In our study, we reviewed all cases of urachal carcinomas 
that were diagnosed and treated at a single institute over 
the past 25 years. To date, there have been no randomized 
trials and fewer than 300 cases reported in the literature 
[9]. Moreover, there have not been any reports from a case 
series or a cohort study including more than 20 cases in a 
single-center series with long-term follow-up from Asia. 
Thus, we conducted this study to evaluate the prognostic 
factors of patients with urachal cancer by using a Bayesian 
model-averaging approach and to analyze prognosis by us-
ing data from the longest follow-up study and largest cohort 
of patients in Asia to date.
MATERIALS AND METHODS
1. Patient cohort
We reviewed the medical records of Severance Hospital 
from January 1988 to May 2012 and identified 41 patients 
who were newly diagnosed with urachal carcinoma. After 
Institutional Review Board approval, patient character-
istics were obtained from medical records. In all patients, 
cystoscopy, abdominopelvic computed tomography, chest 
simple x-ray film, or bone scintigraphy were performed. In 
addition, histopathologic findings from transurethral re-
section specimens, partial cystectomy, or radical cys-
tectomy and radiologic findings were examined to confirm 
urachal carcinoma. 
2. Good clinical practice protocols
The study was performed in agreement with applicable 
laws and regulations, good clinical practices, and ethical 
principles as described in the Declaration of Helsinki. The 
Institutional Review Board of the Severance Hospital ap-
proved this study protocol (approval no. 4-2012-0897).
3. Outcome assessments of urachal cancer
All patients were classified by both the Sheldon staging 
system and the Mayo staging system according to histo-
pathologic reports and preoperative radiologic findings. 
Tumor size was calculated on the basis of the maximal di-
ameter in the pathologic reports. In patients without parti-
al or radical cystectomy, tumor size was measured by using 
the long diameter on computed tomography. Patients who 
underwent adjuvant therapy were defined as those who re-
ceived various regimens of chemotherapy, radiotherapy, or 
both. Histopathologic classifications were based on the 
pathological reports from our institute as follows: (1) muci-
nous adenocarcinoma, (2) nonmucinous adenocarcinoma, 
and (3) other pathologic findings originating from the ur-
achus such as squamous cell carcinoma or signet ring cell 
carcinoma. 
4. Statistical analyses
The end points of our study were 5- and 10-year cancer-spe-
cific survival (CSS) rates. Survival was deﬁned as the time 
from diagnosis until death from urachal carcinoma. 
Patients alive at the final follow-up or who died of other 
causes were censored at that point. Associations between 
patient, tumor, and surgical variables were tested for their 
impact on survival by Pearson chi-square test. Kaplan- 
Meier survival curves were constructed and compared by 
using the log-rank test. The two above-mentioned staging 
systems, age, and tumor size were compared in terms of 
their ability to predict CSS by use of multivariate analysis 
with Kaplan-Meier survival curves and Cox propor-
tional-hazards regression models with forward stepwise 
selection. Additionally, we used Bayesian model averaging 
to identify the best set of predictors for mortality across all 
feasible models on the basis of Bayesian probability theory. 
From these averaged estimates, the posterior probability 
that a coefficient was nonzero was calculated. The posteri-
or probability, P(B≠0), is interpreted as the probability 
that a predictor has an effect. The interpretation of P(B≠0) 
has been categorized as follows: ＜50% is evidence against 
an effect; 50%–75% is weak evidence; 75%–95% is positive 
evidence; 95%–99% is strong evidence; and >99% is very 
strong evidence of an effect. Two-sided tests were per-
formed and p-values ＜0.05 were considered statistically 
signiﬁcant. Statistical analyses were performed with R sta-
tistics software (R ver. 3.0.3; R Foundation for Statistical 
Computing, Vienna, Austria; http://www.r-project.org) by 
using BMA for a Bayesian model-averaging approach.
RESULTS
The general characteristics of the 41 patients who were di-
agnosed with urachal carcinoma at the Severance Hospital 
over the last 25 years are shown in Table 1. Five- and 
10-year CSS rates were 55.9% and 43.4%, respectively (Fig. 
1).
There was no statistical difference in CSS according to 
the patients’ age, which was divided into two groups of ＜55 
and ≥55 years (Fig. 2A). The patients were also divided in-
to two subgroups according to the Sheldon staging system: 
IIIA, IIIB, and IIIC vs. IIID, IVA, and IVB. The subgroup 
with stage IIIA, IIIB, and IIIC showed significantly higher 
10-year CSS in a log-rank test (p=0.004) (Fig. 2B). Ten-year 
CSS was also significantly different according to Mayo 
stage. Two subgroups including Mayo stages I and II vs. 
Mayo stages III and IV were created, and the group of Mayo 
stages I and II showed significantly higher 10-year CSS by 
use of the log-rank test (p＜0.001) (Fig. 2C). 
The histopathological results showed that there were 28 
patients (68.3%) with mucinous adenocarcinoma, 11 
(24.4%) with nonmucinous adenocarcinoma, 2 (4.9%) with 
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TABLE 1. Characteristics of 41 patients with urachal carcinoma
                       Characteristic No. (%)
Sex
    Male 24 (58.5)
    Female 17 (41.5)
Age (y)
    ＜55 27 (65.9)
    ≥55 14 (34.1)
Symptoms and signs
    Hematuria 32 (78.0)
    Suprapubic pain 10 (24.4)
    Voiding difficulty   8 (19.5)
    Palpable infraumbilical mass   7 (17.1)
    Urinary tract infection   3 (7.3)
Cystoscopy (n=34)
    Mass lesion visualized 31 (91.2)
    Normal examination   4 (11.8)
Computed tomography (n=35)
    Solid mass 28 (80.0)
    Calcification   3 (8.6)
    Thickened bladder dome   3 (8.6)
    Mixed solid and cystic mass   3 (8.6)
    Normal finding   1 (2.9)
Treatment modality
    Partial cystectomy 29 (70.7)
    Radical cystectomy   5 (12.2)
    Transurethral resection   3 (7.3)
    Pelvic exenteration   1 (2.4)
    Neoadjuvant chemotherapy   3 (7.3)
Tumor size (cm)  
    ＜5 12 (29.3)
    ≥5 29 (70.7)
Histologic pattern 
    Adenocarcinoma, mucinous 28 (68.3)
    Adenocarcinoma, nonmucinous 10 (24.4)
    Signet ring carcinoma   2 (4.9)
    Squamous cell carcinoma   1 (2.4)
Tumor stage (Sheldon)
    IIIA 16 (39.0)
    IIIB   1 (2.4)
    IIIC   5 (12.2)
    IIID 11 (26.8)
    IVA   3 (7.3)
    IVB   5 (12.2)
Tumor stage (Mayo)
    I 18 (43.9)
    II 14 (34.1)
    III   4 (9.8)
    IV   5 (12.2)
Positive surgical margin (n=25)   4 (16.0)
FIG. 1. Cancer-specific survival (CSS) in 41 patients in the study 
cohort. Five- and 10-year CSS rates were 55.9% and 43.4%, 
respectively.
signet ring cell carcinoma, and 1 (2.4%) with squamous cell 
carcinoma. The patients were then divided into two sub-
groups according to histopathological results: those with 
mucinous adenocarcinoma and those with other histo-
pathologic findings. Ten-year CSS was significantly differ-
ent between the two subgroups (p=0.005) (Fig. 2D). For our 
patient cohort, the mean tumor size was 6.31±2.84 cm. The 
patients were divided into two subgroups according to tu-
mor size: ＜5 cm (n=12, 29.3%) vs. ≥5 cm (n=29, 70.7%). 
There were significant differences between the two sub-
groups according to a log-rank test (p=0.023) (Fig. 2E). 
Adjuvant therapy was performed in 17 patients: 15 and 
1 patients underwent chemotherapy and radiotherapy, re-
spectively, and only 1 patient underwent both treatments. 
Subgroups were created according to whether patients did 
or did not undergo adjuvant therapy. 
In univariate and multivariate Cox proportional-ha-
zards regression models, we controlled for age, size, 
Sheldon staging system, Mayo staging system, histology, 
and adjuvant chemotherapy. In the univariate analysis, 
larger tumor size, higher Sheldon and Mayo stages, and 
nonmucinous adenocarcinoma were significant factors of 
poor prognosis for urachal carcinoma. In the multivariate 
Cox proportional-hazards regression analysis with Shel-
don stage, there were no independent prognostic factors in 
three variables. However, in the multivariate analysis 
with Mayo stage, higher Mayo stage (hazard ratio [HR], 
18.327; 95% confidence interval [CI], 3.986–84.270; p
＜0.001) and larger tumor size (HR, 6.617; 95% CI, 1.323–
33.086; p=0.021) were independent factors for poor prog-
nosis (Table 2). 
By use of the Bayesian model-averaging approach, high-
er Mayo stage was suggested as the most significant factor 
for mortality of urachal carcinoma (P(B≠0)=100%); the 
second was larger size of urachal cancer (P(B≠0)=95.8%) 
(Table 3).
DISCUSSION
Urachal cancer was initially reported to have a 5-year sur-
vival rate of 6.5% to 15%, which represents a poor prognosis 
[10,11]. This poor prognosis is mainly attributable to the 
fact that the tumor occurs at the urachal remnant, which 
is located at the anterior portion of the bladder, thereby de-
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FIG. 2. (A) ＜55 y vs. ≥55 y; (B) Sheldon stage IIIA, IIIB, and 
IIIC vs. Sheldon stage IIID, IVA, and IVB; (C) Mayo stages I 
and II vs. Mayo stages III and IV; (D) mucinous adenocar-
cinoma vs. others; and (E) ＜5 cm vs. ≥5 cm. 
laying symptom progression and making an early diag-
nosis difficult. In addition, the bladder wall is easily in-
vaded owing to the absence of capsular formation in the 
bladder, and complete surgical resection is often un-
successful because of inaccurate preoperative diagnosis 
[12]. Metastases initially are also seen primarily in the pel-
vic lymph nodes, locally in the space of Retzius, or at the 
apex of the bladder, and distant metastatic sites are noted 
in multiple organs, including liver, lung, bone, brain, and 
lymph nodes [5,13,14]. However, according to studies con-
ducted since the 1980s, the 5-year survival rate has been 
reported to be up to 40% to 61% [15]. In the present study, 
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TABLE 2. Univariate and multivariate cox hazard proportional regression model for various factors
                                Covariate HR 95% CI p-value
Univariate
    Age (＜55 y vs. ≥55 y) 0.969 0.885–2.807 0.954
    Tumor size (≥5 cm vs. ＜5 cm) 4.922 1.100–22.030 0.037
    Sheldon stage (IIID, IVA, and IVB vs. IIIA, IIIB, and IIIC) 4.627 1.521–14.080 0.007
    Mayo stage (III and IV vs. I and II) 11.891 3.782–37.391 ＜0.001
    Other (pathology vs. mucinous adenocarcinoma) 3.772 1.384–10.308 0.010
Multivariate with Sheldon stagea
    Tumor size (≥5 cm vs. ＜5 cm) 4.275 0.895–20.415 0.069
    Sheldon stage (IIID, IVA, and IVB vs. IIIA, IIIB, and IIIC) 3.379 0.902–12.659 0.071
    Other (pathology vs. mucinous adenocarcinoma) 2.269 0.698–7.382 0.173
Multivariate with Mayo stagea
    Tumor size (≥5 cm vs. ＜5 cm) 6.617 1.323–33.086 0.021
    Mayo stage (III and IV vs. I and II) 18.327 3.986–84.270 ＜0.001
    Other (pathology vs. mucinous adenocarcinoma) 2.721 0.860–8.606 0.088
HR, hazard ratio; CI, confidence interval.
TABLE 3. Cox proportional hazard regression model coefﬁcient 
estimates derived by using bayesian model averaging
                      Predictor Coefficient P(B≠0)
Tumor size (≥5 cm vs. ＜5 cm) 1.886 95.8
Sheldon stage (IIID, IVA, and IVB vs. 0.250 30.4
  IIIA, IIIB, and IIIC)
Mayo stage (III and IV vs. I and II) 2.848 100
Other (pathology vs. mucinous 0.482 49.0
  adenocarcinoma)
P(B≠0), the posterior probability that a coefficient is nonzero.
the 5-year CSS and 10-year CSS were 53.0% and 45.5%, 
respectively. 
Many studies with long-term follow-up of urachal cancer 
have recently been reported. Herr et al. [16] conducted a 
study on 50 patients who underwent extended partial cys-
tectomy and reported that a survival rate of 70% was shown 
in a median 5-year follow-up, that pathological tumor stage 
and negative surgical margin were the most critical surviv-
al predictors, and that wide resection of the tumor and ur-
achus was important. Pinthus et al. [17] conducted a 
25-year follow-up study on the survival rate of 40 patients 
with urachal cancer and reported that the 5-year and 
10-year overall survival rates were 61.3% and 49.2%, re-
spectively, in a median 6-year follow-up, and that the sur-
vival rate was significantly higher in 32 patients who un-
derwent a surgical treatment than in the remaining pa-
tients who did not undergo the surgical treatment. Howev-
er, because surgical treatment was associated with a lower 
preoperative stage than neoadjuvant chemotherapy, it is 
inconclusive whether surgical treatment improves surviv-
al more than does nonsurgical treatment. In this study, the 
three patients who did not undergo surgical treatment had 
Mayo stages III (one patient) and IV (two patients) disease, 
which are higher stages than those of the other patients. 
Ashley et al. [5] reported that 5-year CSS was 49% in 66 
patients with urachal cancer in a 54-year long-term fol-
low-up. A multivariate analysis reported that grade and 
surgical margin were prognostic factors that are sig-
nificantly associated with survival and that lymphadenec-
tomy and adjuvant therapy had no survival benefit. That 
study concluded that no effective treatment was available 
for metastatic urachal cancer. 
In the present study, survival was analyzed by dividing 
the patients into the adjuvant therapy group and the no ad-
juvant therapy group. As a result, the survival rate was sig-
nificantly lower in the adjuvant therapy group than in the 
no adjuvant therapy group. This is likely attributed to the 
fact that the patients who underwent adjuvant therapy 
showed local recurrence (45.5%) or metastasis during the 
follow-up (27.3%) or had a high disease stage (Mayo stage 
III, one patient; Mayo stage IV, one patient) upon diag-
nosis. Siefker-Radtke [18] recently reported that the risk 
factors of urachal carcinoma associated with recurrence 
following surgery include (1) positive margin, (2) positive 
lymph node, (3) other metastasis, and (4) failure to resect 
the umbilicus en bloc with the urachal ligament and 
bladder. The aforementioned risk factors were significan-
tly consistent with those shown in the results of this study. 
In Asia, Ghazizadeh et al. [19] reported a secondary anal-
ysis that was conducted on 157 patients with urachal can-
cer collected from the Japanese literature in the past 49 
years. They reported an incidence of 0.55% to 1.2%, higher 
than that of Western countries, and a 5-year survival rate 
of 6% in 66 patients. Because their study, however, was a 
secondary study via a literature review from 1932 to 1981, 
it seems unsuitable for the current diagnosis and treat-
ment of urachal cancer. In China, Shou et al. [20] reported 
that 12 patients with cancer of urachal origin were ob-
served out of 27 patients with bladder adenocarcinoma. In 
their study, the overall 5-year survival rate was 25.9% in 
the patients with urachal carcinoma. The low survival rate 
shown in this study is likely attributable to the fact that 
the study had a small sample size of 12 patients despite the 
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TABLE 4. Previous studies on cancer-free survival for urachal carcinoma
                Total Alive patients, Median 5-Year 10-Year 
                Study
                patients n (%) follow-up (y) survival rate survival rate
Sheldon et al. [4] 5   3 (60) 5 - -
Johnson et al. [23] 14   7 (50) 6 - -
Grignon et al. [24] 24 15 (61) 5 64%a 46%a
Herr [25] 12 10 (83) 8 - -
Henly et al. [13] 34 15 (43) 5 43%a -
Asano et al. [21] 15   9 (60) 7 - -
Santucci et al. [26] 17 15 (88) 6 - -
Dandekar et al. [27] 21   9 (46) 5 46%b -
Shou et al. [20] 12   4 (35) 5 26%b -
Siefker-Radtke et al. [28] 35 16 (46) 5 40%b -
Wright et al. [29] 71 34 (48) 5 48%b -
Pinthus et al. [17] 32 20 (61) 6 51%b 31%b
Ashley et al. [5] 60 29 (49) 5 49%a -
Herr et al. [16] 50 35 (70) 5 61.3%a 49.2%a
Yazawa et al. [30] 10   6 (60) 4 - -
Present 41 25 (61) 5 56%a 43%a
a:Cancer-specific survival. b:Overall survival.
long-term follow-up starting from 1970. In Japan, Asano 
et al. [21] reported that 9 of 15 urachal carcinoma patients 
(60%) survived after total cystectomy. Their study, how-
ever, did not report the survival rate and had no patient 
group for other treatment modalities. In Korea, Cho et al. 
[22] analyzed the oncologic outcomes of 31 patients (17 ura-
chal and 14 nonurachal adenocarcinoma patients). They 
classified the patients into urachal and nonurachal groups 
according to Sheldon criteria, followed by analysis. No sig-
nificant difference in CSS was found between the urachal 
and nonurachal groups for a mean follow-up period of 4.5 
years, but the tumor size (≤4 cm) and histological type af-
fected the survival rate in the case of mucinous adeno-
carcinoma. Their study had disadvantages in that it had 
a small size of 17 patients with cancer of urachal origin de-
spite the long-term follow-up results, as shown in Shou et 
al. [20], and that it did not clearly present the median fol-
low-up period and overall survival or CSS. A comparative 
analysis of previous studies is summarized in Table 4. 
The present study was conducted to investigate the sur-
vival of 41 patients with urachal cancer. It is the first study 
with long-term follow-up and a large sample size in Asia, 
and various risk factors were analyzed. Both the Sheldon 
staging system and the Mayo staging system showed a sig-
nificant difference in the survival rate according to group. 
However, only the Mayo system showed a significant differ-
ence in both the multivariate analysis and the Bayesian 
model-averaging approach. This result is likely attribut-
able to the fact that the Mayo system proposed by Ashley 
et al. [5] in 2006 is simpler and has four stages that are eas-
ier to apply in clinical practice than is the Sheldon system. 
The clinical significance of tumor size is still controversial. 
Cho et al. [22] reported that the size significantly affected 
CSS. In most studies, however, tumor size was not included 
in the staging system, which means that it might not affect 
the survival rate. In a Bayesian model-averaging ap-
proach, higher tumor size was the second higher posterior 
probability rank. In the future, a new staging system 
should consider larger tumor size as a prognostic factor fol-
lowing systematic review and meta-analysis for CSS of 
urachal cancer. 
CONCLUSIONS
We have reported 41 cases of urachal carcinoma seen at a 
single institute over a recent 25-year period. The patient 
5- and 10-year CSS rates were 55.9% and 43.4%, respec-
tively. According to the survival rate in our study, the Mayo 
staging system might be more effective than the Sheldon 
staging system. In addition, higher Mayo stage and larger 
tumor size may be risk factors that can be used to predict 
CSS of urachal carcinoma. 
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